-
公开(公告)号：US5773453A
公开(公告)日：1998-06-30
申请号：US425057
申请日：1995-04-19
IPC分类号： A61K31/455 , A61K31/54 , A61K31/60 , A61K31/44 , A61K31/19 , A61K31/415
CPC分类号： A61K31/60 , A61K31/455 , A61K31/54 , A61K31/621 , Y10S514/823
摘要： The present invention concerns methods for reducing cutaneous flushing in a patient to whom niacin is administered. According to the present method, two or more doses of a nonsteroidal anti-inflammatory drug are administered to a patient prior to administering niacin. Alternatively, the nonstcroidal anti-inflammatory drug can be administered concurrently with niacin administration. The nonstcroidal anti-inflammatory drug can be aspirin, ibuprofen, indomethacin, phenylbutazone, or naproxen. The nonsteroidal anti-inflammatory drug is administered in an amount effective to reduce cutaneous flushing caused by the niacin, and is administered in an amount up to 160 mg for aspirin and ibuprofen, 10 mg for indomethacin, and 100 mg for phenylbutazone and naproxen.
摘要翻译： 本发明涉及减少给予烟酸的患者的皮肤潮红的方法。 根据本方法，在给予烟酸之前，向患者施用两种或更多剂量的非甾体抗炎药。 或者，非骨骼消炎药可以与施用烟酸同时施用。 非结构性抗炎药可以是阿司匹林，布洛芬，吲哚美辛，保泰松或萘普生。 非甾体抗炎药以有效减少由烟酸引起的皮肤潮红的量施用，并且以阿司匹林和布洛芬为最高为160mg，吲哚美辛为10mg，保泰松和萘普生为100mg。
-
公开(公告)号：US5981555A
公开(公告)日：1999-11-09
申请号：US937669
申请日：1997-09-26
IPC分类号： A61K31/455 , A61K31/54 , A61K31/60 , A61K31/715 , A61K31/33
CPC分类号： A61K31/60 , A61K31/455 , A61K31/54 , A61K31/621 , Y10S514/823
摘要： The present invention concerns composition, kits and methods for reducing the flushing effect (cutaneous erythema) of an antilipemic drug, for treating hyperlipemia, for improving the effectiveness of an anti-platelet aggregating drug (e.g., in nonresponders) and for treating thrombosis. The present compositions and kits for reducing the flushing effect and for treating hyperlipemia contain an antilipemic drug (such as niacin) and either a sustained release NSAID (such as aspirin) or an NSAID and a carboxylic acid compound other than the NSAID and antilipemic drug. The kits contain (a) pre-dosages of the NSAID and optional carboxylic acid compound and (b) an antilipemic dosage of the antilipemic drug, which optionally may be combined with NSAID and optional carboxylic acid compound in an amount effective to maintain the reduction of the flushing effect. The present method of treating hyperlipemia comprises predosing the patient with a sustained release NSAID or an NSAID and a carboxylic acid compound other than the NSAID and antilipemic drug at least 2 hours before administering the antilipemic drug. The present compositions and kits for increasing the effectiveness of an anti-platelet aggregating drug contain an NSAID such as aspirin, niacin or a congener thereof, and optionally, a carboxylic acid other than the NSAID, such as citric acid.
摘要翻译： 本发明涉及用于降低抗血脂药物的冲洗作用（皮肤红斑），用于治疗高脂血症，改善抗血小板聚集药物（例如，在无应答者中）和用于治疗血栓形成的效果的组合物，试剂盒和方法。 用于降低冲洗效果和用于治疗高脂血症的本发明组合物和试剂盒含有抗血脂药物（例如烟酸）和持续释放的NSAID（例如阿司匹林）或NSAID和除NSAID和抗脂药物之外的羧酸化合物。 试剂盒包含（a）NSAID和任选的羧酸化合物的预先剂量和（b）抗脂药物的抗血药剂量，其任选地可以与NSAID和任选的羧酸化合物组合，其量有效地维持 冲洗效果。 本发明治疗高脂血症的方法包括在施用抗血脂药物前至少2小时预先给予具有持续释放NSAID或NSAID和除NSAID和抗脂药物之外的羧酸化合物的患者。 用于增加抗血小板聚集药物的有效性的本发明组合物和试剂盒含有NSAID，例如阿司匹林，烟酸或其同类物，以及任选的除NSAID之外的羧酸，例如柠檬酸。
-
3.发明授权
公开(公告)号：US5945295A
公开(公告)日：1999-08-31
申请号：US995480
申请日：1997-12-22
CPC分类号： G01N33/88
摘要： This invention relates to a method to assess food spoilage ex vivo by quantification of prostanoid compounds and their metabolites produced by a noncyclooxygenase free radical catalyzed mechanism.
摘要翻译： 本发明涉及一种通过定量前列腺素类化合物及其通过非环氧合酶自由基催化机制产生的代谢物来评估食物变质的方法。
-
公开(公告)号：US5891622A
公开(公告)日：1999-04-06
申请号：US28543
申请日：1998-02-24
CPC分类号： G01N33/88
摘要： A method to assess oxidative stress in vivo by measuring the amount of free, esterified and glucuronidated forms of isoprostanes (8EPGF2) in a biological sample which contains the isoprostanes is disclosed. The method further includes determining the amount of total isoprostanes present in the sample. This amount is compared with a control sample. The oxidative stress is determined through the comparison wherein the amount of isoprostanes increase in the sample isolated from an organism undergoing oxidative stress compared to the control. Alternatively the method of the present invention provides for only the measurement of the glucuronidated form wherein the amount of glucuronidated isoprostanes increase in the sample isolated from an organism undergoing oxidative stress compared to the control.
摘要翻译： 公开了一种通过测量包含异前列烷烷的生物样品中游离，酯化和葡糖醛酸化形式的异前列烷（8EPGF2）的量来评估体内氧化应激的方法。 该方法还包括测定样品中存在的总异前列烷烷的量。 将该量与对照样品进行比较。 通过比较确定氧化应激，其中与对照相比，从经历氧化应激的生物体分离的样品中异前列烷的量增加。 或者，本发明的方法仅提供葡萄糖醛酸化形式的测量，其中与对照相比，从与经历氧化应激的生物体分离的样品中葡萄糖醛酸化的异前列烷的量增加。
-
公开(公告)号：US5858696A
公开(公告)日：1999-01-12
申请号：US912440
申请日：1997-08-18
CPC分类号： G01N33/88
摘要： This invention relates to a method to assess oxidative stress in vivo by quantification of prostaglandin F.sub.2 -like compounds and their metabolites produced by a noncyclooxygenase free radical catalyzed mechanism.
摘要翻译： 本发明涉及通过定量前列腺素F2样化合物及其通过非环氧合酶自由基催化机制产生的代谢物来评估体内氧化应激的方法。
-
公开(公告)号：US5700654A
公开(公告)日：1997-12-23
申请号：US304147
申请日：1994-09-12
CPC分类号： G01N33/88
摘要： This invention relates to a method to assess oxidative stress in vivo by quantification of prostaglandin F.sub.2 -like compounds and their metabolites produced by a noncyclooxygenase free radical catalyzed mechanism.
摘要翻译： 本发明涉及通过定量前列腺素F2样化合物及其通过非环氧合酶自由基催化机制产生的代谢物来评估体内氧化应激的方法。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.021 秒)
